Cancer stem cell antigen vaccines and methods
Method of stimulating an immune response (e.g., to treat cancer) include administering to a patient a composition including dendritic cells that present cancer stem cell antigens. Compositions including cancer stem cell antigens are also provided herein.
1. A method of treating glioblastoma in a patient, the method comprising:
obtaining a population of dendritic cells; contacting the dendritic cells with a glioblastoma cancer stem cell antigen composition consisting essentially of antigens derived from isolated glioblastoma cancer stem cells under conditions such that the dendritic cells present glioblastoma cancer stem cell antigens; and
administering to a patient a composition comprising the dendritic cells.
2. The method of claim 1 , wherein the dendritic cells are autologous.
3. The method of claim 1 , wherein the dendritic cells are allogeneic.
4. The method of claim 1 , wherein the glioblastoma cancer stem cell antigen composition is obtained from glioblastoma cancer stem cells isolated from a glioblastoma tumor.
5. The method of claim 1 , wherein the glioblastoma cancer stem cell antigen composition comprises a lysate of glioblastoma cancer stem cells.
6. The method of claim 1 , wherein the glioblastoma cancer stem cell antigen composition comprises an acid eluate of glioblastoma cancer stem cells.
7. The method of claim 5 , wherein the glioblastoma cancer stem cells express CD133.
8. The method of claim 1 , wherein the glioblastoma cancer stem cell antigen composition comprises one or more isolated peptides of CD133, CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi1), maternal embryonic leucine zipper kinase (MELK), GLI 1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin.
9. The method of claim 8 , wherein the one or more isolated peptides are synthetic.
10. A method of treating glioblastoma in a patient, the method comprising:
administering to a patient a composition consisting essentially of dendritic cells that present glioblastoma cancer stem cell antigens.
11. The method of claim 10 , wherein the glioblastoma cancer stem cell antigens are obtained from glioblastoma cancer stem cells isolated from a glioblastoma tumor.
12. The method of claim 10 , wherein the glioblastoma is a recurrent glioblastoma.
13. The method of claim 1 , wherein the glioblastoma is a recurrent glioblastoma cancer.
14. The method of claim 1 , wherein the patient is human.
15. The method of claim 10 , wherein the patient is human.